What is the dosage of Lucentis?

Lucentis is available in 4 dosages, including 6 mg/ml Prefilled Syringe 0.05 ml, 6 mg/ml Injection 0.05 ml, 10 mg/ml Prefilled Syringe 0.05 ml and 10 mg/ml Injection 0.05 ml

What is Lucentis mechanism of action?

Lucentis mechanism of action is Vascular Endothelial Growth Factor Inhibitors

Lucentis Prescribing & Dosing Schedule

Q: What does Lucentis treat?

Lucentis treats Diabetic Retinopathy, Macular Edema and Retinal Vein Occlusion

Q: What is Lucentis made of?

Lucentis contains ranibizumab which is a Vascular Endothelial Growth Factor Inhibitor

Q: How is Lucentis administered?

Lucentis is administered as a Injectable

Dosage & Administration

For ophthalmic intravitreal injection only

* Neovascular (Wet) Age-Related Macular Degeneration (AMD) :
LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
* Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.
* Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.

* Macular Edema Following Retinal Vein Occlusion (RVO) :
LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
* Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) :
LUCENTIS 0.3 mg (0.05 mL of 6 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
* Myopic Choroidal Neovascularization (mCNV) :
LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed.

Get Your Patient on Lucentis

See your patient's specific prior authorization requirements including coverage restrictions and step therapies

Or select your Insurance from the list below:

Lucentis Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

Lucentis Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form

Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form

Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form

Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form

Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form

Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form

Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form

Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form

Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form

Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form

Coverage Authorization Appeals

Complete Letter of Medical Necessity

Benefits investigation

Patient Consent Form

Patient Consent Form - Spanish

Prescriber Service Form

Lucentis Preferred Pharmacy

Pharmacy List

Lucentis Financial Assistance Options

Copay savings program

Prescriber Service Form

Patient Consent Form

Patient Consent Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

Prescriber Service Form

Patient Consent Form

Patient Consent Form - Spanish

Genentech Patient Assistance Program Prescriber Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.